Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Aldeyra Therapeutics Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 30.00m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 30.33m for operations while cash used for financing totalled 1.27m.
Cash flow per share | -0.6348 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.65 |
---|---|
Tangible book value per share | 1.65 |
More ▼
Balance sheet in USDView more
Current ratio | 4.55 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.155 |
---|---|
Total debt/total capital | 0.1342 |
More ▼